Higher dose alglucosidase alfa is associated with improved overall survival in infantile-onset Pompe disease (IOPD): data from the Pompe Registry

被引：0
作者：
Priya S. Kishnani
David Kronn
Shugo Suwazono
Alexander Broomfield
Juan Llerena
Zuhair Nasser Al-Hassnan
Julie L. Batista
Kathryn M. Wilson
Magali Periquet
Nadia Daba
Andreas Hahn
Yin-Hsiu Chien
机构：
[1] Duke University Medical Center,Division of Medical Genetics, Department of Pediatrics
[2] New York Medical College,Department of Pathology and Pediatrics
[3] National Hospital Organization Okinawa National Hospital,Center for Clinical Neuroscience
[4] Central Manchester Foundation Trust,Willink Biochemical Genetics Unit, Manchester Center for Genomic Medicine, St Mary’s Hospital
[5] Instituto Fernandes Figueira/FIOCRUZ,Centro de Genética Médica
[6] King Faisal Specialist Hospital and Research Center,Department of Medical Genomics, Center for Genomic Medicine
[7] Sanofi,Department of Child Neurology
[8] Navitas Data Sciences,Department of Medical Genetics and Pediatrics
[9] Sanofi,undefined
[10] Sanofi,undefined
[11] University Hospital Giessen,undefined
[12] National Taiwan University Hospital,undefined
来源：
Orphanet Journal of Rare Diseases | / 18卷
关键词：
Alglucosidase alfa; Dose; Enzyme replacement therapy; Infantile onset Pompe disease; Pompe disease; Pompe registry;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 35 条
  • [21] Real-world data of in-hospital administration of alglucosidase alfa in French patients with Pompe disease: results from the National Claims Database
    Attarian, Shahram
    Campana, Emmanuelle Salort
    Perrier, Stanislas
    Afonso, Marion
    Karam, Pierre
    Hai, Nassima
    Laforet, Pascal
    [J]. JOURNAL OF NEUROLOGY, 2024, : 5846 - 5852
  • [22] An immune tolerance approach using transient low-dose methotrexate in the ERT-naive setting of patients treated with a therapeutic protein: experience in infantile-onset Pompe disease
    Kazi, Zoheb B.
    Desai, Ankit K.
    Troxler, R. Bradley
    Kronn, David
    Packman, Seymour
    Sabbadini, Marta
    Rizzo, William B.
    Scherer, Katalin
    Abdul-Rahman, Omar
    Tanpaiboon, Pranoot
    Nampoothiri, Sheela
    Gupta, Neerja
    Feigenbaum, Annette
    Niyazov, Dmitriy M.
    Sherry, Langston
    Segel, Reeval
    McVie-Wylie, Alison
    Sung, Crystal
    Joseph, Alexandra M.
    Richards, Susan
    Kishnani, Priya S.
    [J]. GENETICS IN MEDICINE, 2019, 21 (04) : 887 - 895
  • [23] A favorable outcome in an infantile-onset Pompe patient with cross reactive immunological material (CRIM) negative disease with high dose enzyme replacement therapy and adjusted immunomodulation
    Curelaru, Shiri
    Desai, Ankit K.
    Fink, Daniel
    Zehavi, Yoav
    Kishnani, Priya S.
    Spiegel, Ronen
    [J]. MOLECULAR GENETICS AND METABOLISM REPORTS, 2022, 32
  • [24] Safety and efficacy of avalglucosidase alfa in individuals with infantile-onset Pompe disease enrolled in the phase 2, open-label Mini-COMET study: The 6-month primary analysis report
    Kishnani, Priya S.
    Kronn, David
    Brassier, Anais
    Broom, Alexander
    Davison, James
    Hahn, Si Houn
    Kumada, Satoko
    Labarthe, Francois
    Ohki, Hirotaka
    Pichard, Samia
    Prakalapakorn, S. Grace
    Haack, Kristina An
    Kittner, Barbara
    Meng, Xianzhang
    Sparks, Susan
    Wilson, Catherine
    Zaher, Atef
    Chien, Yin-Hsiu
    [J]. GENETICS IN MEDICINE, 2023, 25 (02)
  • [25] 36-Months follow-up assessment after cessation and resuming of enzyme replacement therapy in late onset Pompe disease: data from the Swiss Pompe Registry
    Olivier Scheidegger
    Daniela Leupold
    Rafael Sauter
    Oliver Findling
    Kai Michael Rösler
    Thomas Hundsberger
    [J]. Journal of Neurology, 2018, 265 : 2783 - 2788
  • [26] 36-Months follow-up assessment after cessation and resuming of enzyme replacement therapy in late onset Pompe disease: data from the Swiss Pompe Registry
    Scheidegger, Olivier
    Leupold, Daniela
    Sauter, Rafael
    Findling, Oliver
    Rosler, Kai Michael
    Hundsberger, Thomas
    [J]. JOURNAL OF NEUROLOGY, 2018, 265 (12) : 2783 - 2788
  • [27] Hypersensitivity infusion-associated reactions induced by enzyme replacement therapy in a cohort of patients with late-onset Pompe disease: An experience from the French Pompe Registry
    Lessard, Lola E. R.
    Tard, Celine
    Salort-Campana, Emmanuelle
    Sacconi, Sabrina
    Behin, Anthony
    Bassez, Guillaume
    Orlikowski, David
    Merle, Philippe
    Nollet, Sylvain
    Gallay, Laure
    Berard, Frederic
    Robinson, Philip
    Bouhour, Francoise
    Laforet, Pascal
    [J]. MOLECULAR GENETICS AND METABOLISM, 2023, 139 (03)
  • [28] Home-Based Infusion of Alglucosidase Alfa Can Safely be Implemented in Adults with Late-Onset Pompe Disease: Lessons Learned from 18,380 Infusions
    Ditters, Imke A. M.
    van Kooten, Harmke A. A.
    van der Beek, Nadine A. M. E.
    Hardon, Jacqueline F. F.
    Ismailova, Gamida
    Brusse, Esther
    Kruijshaar, Michelle E. E.
    van der Ploeg, Ans T. T.
    van den Hout, Johanna M. P.
    Huidekoper, Hidde H. H.
    [J]. BIODRUGS, 2023, 37 (05) : 685 - 698
  • [29] Long-term outcomes of very early treated infantile-onset Pompe disease with short-term steroid premedication: experiences from a nationwide newborn screening programme
    Yang, Chia-Feng
    Liao, Ting-Wei Ernie
    Chu, Yen-Ling
    Chen, Li-Zhen
    Huang, Ling-Yi
    Yang, Tsui-Feng
    Ho, Hui-Chen
    Kao, Shu-Min
    Niu, Dau-Ming
    [J]. JOURNAL OF MEDICAL GENETICS, 2023, 60 (05) : 430 - 439
  • [30] Long-Term Outcome of Infantile Onset Pompe Disease Patients Treated with Enzyme Replacement Therapy - Data from a German-Austrian Cohort
    Pfrimmer, Charlotte
    Smitka, Martin
    Muschol, Nicole
    Husain, Ralf A.
    Huemer, Martina
    Hennermann, Julia B.
    Schuler, Rahel
    Hahn, Andreas
    [J]. JOURNAL OF NEUROMUSCULAR DISEASES, 2024, 11 (01) : 167 - 177
1234